Response to thalidomide in multiple myeloma*
| Patient . | Sex† . | Prior therapies . | Prior stem cell transplant . | Maximum change M protein‡ . | Duration of thalidomide therapy (mo) . | Maximum daily dose thalidomide . | Current status (daily thalidomide dose) . |
|---|---|---|---|---|---|---|---|
| 1 | M | 3 | Yes | − 58% (PR) | 8.5 | 200 mg | Continued response (200 mg) |
| 2 | F | 5 | No | − 78% (PR) | 6.0 | 400 mg | Continued response (400 mg) |
| 3 | F | 1 | Yes | + 16% (SD) | 6.5 | 100 mg | Continued response (100 mg) |
| 4 | M | 6 | No | − 56% (PR) | 9.0 | 200 mg | Continued response (200 mg) |
| 5 | F | 1 | No | − 62% (PR) | 5.5 | 200 mg | Continued response (50 mg) |
| 6 | F | 5 | Yes | − 100% (CR) | 13 | 500 mg | Continued response (50 mg) |
| 7 | M | 9 | Yes | − 54% (PR) | 10 | 800 mg | Progressed (800 mg) |
| 8 | F | 5 | Yes | − 68% (PR) | 4.0 | 200 mg | Continued response, discontinued |
| 9 | F | 5 | No | − 90% (PR) | 7.5 | 400 mg | Continued response (400 mg) |
| 10 | M | 5 | Yes | − 9% (SD) | 1.5 | 400 mg | Progressed |
| 111-153 | F | 4 | Yes | − 59% (PR) | 5.5 | 400 mg | Progressed |
| 121-153 | M | 4 | Yes | − 64% (PR) | 7.0 | 400 mg | Progressed |
| 131-153 | F | 3 | Yes | − 14% (SD) | 4.5 | 400 mg | Progressed |
| 141-153 | F | 2 | Yes | − 55% (PR) | 4.0 | 800 mg | Continued response (800 mg) |
| 15 | F | 1 | No | − 31% (SD) | 6.0 | 400 mg | Continued response (400 mg) |
| 16 | F | 1 | No | − 12% (SD) | 4.5 | 400 mg | Progressed |
| 17 | M | 2 | No | − 55% (PR) | 6.0 | 200 mg | Continued response (100 mg) |
| Patient . | Sex† . | Prior therapies . | Prior stem cell transplant . | Maximum change M protein‡ . | Duration of thalidomide therapy (mo) . | Maximum daily dose thalidomide . | Current status (daily thalidomide dose) . |
|---|---|---|---|---|---|---|---|
| 1 | M | 3 | Yes | − 58% (PR) | 8.5 | 200 mg | Continued response (200 mg) |
| 2 | F | 5 | No | − 78% (PR) | 6.0 | 400 mg | Continued response (400 mg) |
| 3 | F | 1 | Yes | + 16% (SD) | 6.5 | 100 mg | Continued response (100 mg) |
| 4 | M | 6 | No | − 56% (PR) | 9.0 | 200 mg | Continued response (200 mg) |
| 5 | F | 1 | No | − 62% (PR) | 5.5 | 200 mg | Continued response (50 mg) |
| 6 | F | 5 | Yes | − 100% (CR) | 13 | 500 mg | Continued response (50 mg) |
| 7 | M | 9 | Yes | − 54% (PR) | 10 | 800 mg | Progressed (800 mg) |
| 8 | F | 5 | Yes | − 68% (PR) | 4.0 | 200 mg | Continued response, discontinued |
| 9 | F | 5 | No | − 90% (PR) | 7.5 | 400 mg | Continued response (400 mg) |
| 10 | M | 5 | Yes | − 9% (SD) | 1.5 | 400 mg | Progressed |
| 111-153 | F | 4 | Yes | − 59% (PR) | 5.5 | 400 mg | Progressed |
| 121-153 | M | 4 | Yes | − 64% (PR) | 7.0 | 400 mg | Progressed |
| 131-153 | F | 3 | Yes | − 14% (SD) | 4.5 | 400 mg | Progressed |
| 141-153 | F | 2 | Yes | − 55% (PR) | 4.0 | 800 mg | Continued response (800 mg) |
| 15 | F | 1 | No | − 31% (SD) | 6.0 | 400 mg | Continued response (400 mg) |
| 16 | F | 1 | No | − 12% (SD) | 4.5 | 400 mg | Progressed |
| 17 | M | 2 | No | − 55% (PR) | 6.0 | 200 mg | Continued response (100 mg) |
As of January 1, 2000.
Male (M) or female (F).
Partial response (PR) is ≥ 50% decrease in M protein; complete response (CR) is absence of M protein on immunofixation and normal bone marrow biopsy; stable disease (SD) is ≤ 50% decrease in M protein; progression is ≥ 25% increase in M protein or progressive clinical disease.
Also received decadron therapy.